The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

ABSTRACT:

SUBMITTER: Marson A 

PROVIDER: S-EPMC8047813 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature